Vivos Inc. Expands IsoPet® Animal Cancer Division in 2025
Vivos Inc. (OTCQB: RDGL) strengthens its IsoPet® division in 2025 with the expansion of clinics, training advancements, and cutting-edge cancer treatments for pets
Vivos Inc. (OTCQB: RDGL) continues to make remarkable progress in veterinary oncology through its IsoPet® Animal Cancer Division. Following a transformative 2024, the company that reshaped the company and expanded their vision, IsoPet® is accelerating its efforts in 2025 with more certified clinics, enhanced training, and expanded collaborations. These developments are designed to provide pet owners with greater access to minimally invasive cancer treatments, revolutionizing the way veterinarians approach oncology care for animals.
Vivos Inc Stock Price Today | OTC RDGL Live Ticker – Investing.com
With cancer affecting millions of pets annually, IsoPet® is positioned to become a leader in non-invasive radiation therapy, delivering targeted, effective, and safer solutions for both small and large animals. Here’s a deeper dive into the company’s latest achievements and future plans.
Expansion of Certified Clinics
One of IsoPet®’s primary goals in 2025 is to expand access to its advanced radiation therapy by certifying more veterinary clinics across the U.S. This year, the company added three major facilities to its growing network:
Brazos Equine Hospital (Texas)
Located in the heart of Texas, Brazos Equine Hospital specializes in equine veterinary care, making it an essential partner in expanding IsoPet®’s applications for horses. This partnership enables equine specialists to utilize IsoPet® technology for treating caudal heel pain and potential tumor applications in horses.
Animal Emergency & Specialty Center (Tennessee)
As a leading emergency and specialty veterinary hospital in Knoxville, this facility provides critical care services for pets suffering from various medical conditions, including cancer. With its new IsoPet® certification, the hospital can now offer advanced radiation therapy as part of its oncology treatments, increasing options for pet owners in the region.
Sumner Veterinary Hospital (Washington)
Dr. Vanessa Rizzo is the lead board-certified medical oncologist at Hope Veterinary Oncology Services working with Sumner Veterinary Hospital who is certified to treat companion animals with IsoPet® Precision Radionuclide Therapy™. Sumner has been delivering outstanding pet care since 1983 and treats a wide variety of pets including exotic and pocket pets.
These three new clinics bring the total number of IsoPet®-certified facilities to 14, with an additional five clinics pending certification. As these numbers continue to grow, more animals across the U.S. will gain access to this life-saving technology.
Advancing Training and Collaborations
To ensure that all certified clinics are equipped with the latest protocols and expertise, IsoPet® has partnered with FX Masse, a renowned training and consulting firm, to enhance veterinary training programs. This collaboration focuses on:
- Standardizing treatment protocols to improve efficacy.
- Providing hands-on training for veterinary professionals administering IsoPet® therapy.
- Ensuring clinics remain up to date with the latest research and advancements in radiation-based cancer treatments.
Additionally, IsoPet® is actively engaging with leading veterinary hospitals and research institutions to explore new applications for its technology. This includes investigating how IsoPet® can be used to:
- Reduce recurrence rates in surgically removed tumors (Margin Therapy).
- Expand applications in larger animals, particularly in equine and livestock oncology.
- Improve treatment outcomes for rare and aggressive cancers in exotic pets.
By investing in training and research, IsoPet® is laying the groundwork for a broader and more effective application of its technology.
Market Engagement and Industry Presence
IsoPet® is also strengthening its presence in the veterinary industry by actively participating in major conferences and networking events. Most recently, the company made a significant impact at VMX, the world’s premier veterinary event in Orlando, Florida.
At this high-profile event, IsoPet® representatives:
- Engaged with veterinary professionals to promote the benefits of IsoPet® therapy for horses and all animals.
- Strengthened partnerships with veterinary hospitals and universities.
- Showcased case studies demonstrating the effectiveness of IsoPet® in treating various cancers.
By actively participating in industry events, IsoPet® is raising awareness, educating veterinarians, and expanding the reach of its innovative cancer treatment for all pets.
Operational Enhancements & Treatment Accessibility
With demand for IsoPet® therapy increasing, the company has made several key operational improvements to ensure a reliable and efficient treatment process:
Biweekly Production Schedules
To prevent delays in treatment availability, IsoPet® has implemented a biweekly production cycle. Allowing veterinarians to treat patients more quickly and effectively.
Volume Pricing for Increased Affordability
One of the biggest barriers to advanced veterinary cancer treatment is cost. To make IsoPet® more affordable for pet owners, the company is introducing volume pricing options. This initiative aims to:
- Lower costs per treatment, making it more accessible to pet owners.
- Encourage more veterinarians to treat with IsoPet®.
- Expand the number of animals receiving treatment by reducing financial constraints.
By addressing both supply chain efficiency and pricing, IsoPet® is ensuring that more pets can benefit from its life-saving cancer treatment technology.
Looking Ahead: IsoPet®’s Future Plans
With a strong momentum heading into the remainder of 2025, Vivos Inc. is focused on several key objectives:
- Expanding the IsoPet® clinic network beyond its current 14 certified locations, ensuring greater national availability.
- Developing new treatment applications for a wider range of cancers in both small and large animals.
- Enhancing production and distribution strategies to keep up with increasing demand.
- Continuing collaborations with veterinary hospitals to refine treatment protocols and push the boundaries of radiation oncology in animals.
Dr. Michael K. Korenko, President & CEO of Vivos Inc., emphasized the company’s mission to make IsoPet® an industry standard in veterinary oncology. By expanding patient access, refining treatment protocols, and fostering strategic collaborations, IsoPet® is poised to transform how cancer is treated in animals worldwide.
For more information, visit www.IsoPet.com or follow IsoPet® on social media.
Developed with the goal of improving the quality of life for pets suffering from cancer, IsoPet® has demonstrated promising results in preclinical trials, showing effectiveness in treating various types of tumors in animals. By offering a localized and minimally invasive treatment option, IsoPet® stands out as a beacon of hope for pet owners and veterinarians seeking innovative solutions for cancer care.
Furthermore, the technology behind IsoPet® parallels advancements made for human treatments with RadioGel™, which has garnered attention as a breakthrough device by the FDA, expediting its review process for clinical trials.
Vivos Inc. Announces IDE Submission for RadioGel™ (tradersque.com)
RadioGel® Technology
RadioGel® is a hydrogel liquid containing yttrium-90 phosphate microparticles, administered directly into a tumor. After injection, it gels within the tumor interstitial spaces to keep the radiation sources in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area, minimizing adverse effects on normal organs and tissues. The short half-life of RadioGel® ensures that more than 90% of its therapeutic radiation is delivered within 10 days, allowing for outpatient procedures without risk to family members.
IsoPet® for Veterinary Use
IsoPet® uses the same technology as RadioGel® for treating animals. It has been tested successfully on feline sarcoma at Washington State University and on canine soft tissue sarcomas at the University of Missouri. The FDA has classified IsoPet® as a medical device and does not require pre-market approval for veterinary use, allowing for revenue generation through sales to university hospitals and private clinics.
Vivos Inc. | RadioGel™ | IsoPet® – (OTCMKTS: RDGL)
Meet the Visionaries Behind Vivos Inc.
Meet the innovative minds driving Vivos Inc. forward in the fight against cancer. Our dedicated team combines expertise, passion, and cutting-edge technology to revolutionize cancer treatment. Learn more about our leaders and their groundbreaking work by visiting Meet The Team | RadioGel™
Disclaimer: This article includes paid promotions. We may receive compensation for promoting certain securities. This could influence our content. Please perform your own due diligence and consult with a financial advisor before making any investment decisions.
